The effects of TRAF6 on proliferation, apoptosis and invasion in osteosarcoma are regulated by miR-124

QINGBING MENG*, WENSHENG ZHANG*, XINGLI XU, JIAN LI, HONGXIN MU, XIAOLAN LIU, LING QIN, XIAOQI ZHU and MINQIAN ZHENG

Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224005, P.R. China

Received June 29, 2016; Accepted January 19, 2018

DOI: 10.3892/ijmm.2018.3458

Abstract. The present study aimed to verify tumor necrosis factor receptor-associated factor 6 (TRAF6) as the target gene of microRNA-124 (miR-124). In addition, the expression of miR-124 was investigated in osteosarcoma tissues and cells, and its effects on the biological characteristics of osteosarcoma cells were determined, in order to provide an experimental and theoretical basis for the application of TRAF6 in the treatment of osteosarcoma. A fluorescence reporter enzyme system was used to verify TRAF6 as a target gene of miR-124, and western blotting was used to detect the effects of miR-124 on the protein expression levels of TRAF6 in cells. The expression levels of miR-124 were detected in osteosarcoma tissues and an osteosarcoma cell line (MG-63) by quantitative polymerase chain reaction (qPCR). In addition, a total of 48 h post-transfection of MG-63 cells with a miR-124 mimic, qPCR was used to detect the expression levels of miR-124, and the effects of miR-124 on the viability of MG-63 human osteosarcoma cells was determined using the MTT method. The effects of miR-124 on the viability of MG-63 human osteosarcoma cells was determined using the MTT method. The effects of miR-124 on the cell cycle progression and apoptosis of MG-63 cells were analyzed by flow cytometry, whereas the effects of miR-124 on the migration of MG-63 cells was detected using the Transwell invasion chamber analysis method. A TRAF6 recombinant expression plasmid (pcDNA3.1-TRAF6) was also constructed, and MG-63 cells were transfected with the recombinant plasmid and a miR-124 mimic, in order to further validate the biological role of miR-124 via the regulation of TRAF6. The results of the present study indicated that, compared with in the normal control group, the expression levels of miR-124 were significantly increased in MG-63 cells transfected with a miR-124 mimic (P<0.01). In addition, the luciferase reporter gene system demonstrated that, compared with in the control group, relative luciferase activity was significantly reduced in the miR-124 mimic group (P<0.01). The results of MTT analysis indicated that cell viability was also significantly reduced in response to the overexpression of miR-124 in MG-63 cells (P<0.01). Flow cytometric analysis demonstrated that the proportion of cells in S phase and G2/M phase was significantly decreased (P<0.01) in cells overexpressing miR-124, and the number of apoptotic cells was significantly increased (P<0.01). Furthermore, the results of the Transwell invasion assay suggested that the number of invasive cells was significantly decreased following enhanced expression of miR-124 (P<0.01). In MG-63 cells overexpressing miR-124 and TRAF6, the results of MTT, flow cytometric and Transwell assay analyses demonstrated that the overexpression of TRAF6 had the opposite biological effects compared to miR-124 overexpression. In conclusion, the present study indicated that the expression levels of miR-124 were downregulated in human osteosarcoma tissues and cells, and that miR-124 is associated with negative regulation of TRAF6 expression; therefore, the role of TRAF6 in primary osteosarcoma may be regulated by miR-124. Therapeutic strategies that enhance miR-124 expression or inhibit TRAF6 expression may be beneficial for the treatment of patients with osteosarcoma.

Introduction

Osteosarcoma, which is also known as osteogenic sarcoma, is a malignant form of bone tumor that more commonly occurs in adolescents and children <20 years old (1); osteosarcoma accounts for ~5% of pediatric tumors (2). Osteosarcoma is associated with high malignancy and rapid progress, and can induce early lung metastasis. Furthermore, osteosarcoma has a high recurrence rate and poor prognosis; the 5-year survival rate of patients with osteosarcoma is only 20%, and it is associated with a heavy burden to family members and society (3-5). In recent years, with the development of neoadjuvant chemotherapy/postoperative adjuvant chemotherapy, and the combination of surgical treatment and radiotherapy, the prognosis of patients with osteosarcoma has improved; however, the 5-year survival rate could only be increased to ~60% (6-8). Numerous studies have been conducted by researchers with regards to the mechanisms underlying the occurrence and development of osteosarcoma; however, the pathogenesis of osteosarcoma remains to be elucidated. Therefore, the pathogenesis of osteosarcoma requires further

*Contributed equally

Key words: osteosarcoma, tumor necrosis factor receptor-associated factor 6, microRNA-124, apoptosis, metastasis
study, in order to provide scientific evidence for the diagnosis, treatment and prognosis of osteosarcoma. Elucidation of the pathogenesis of osteosarcoma may result in more effective control of the pathogenic process of osteosarcoma, and may improve patient prognosis, and reduce the burden on patients, families and society (9,10).

Tumor occurrence and development are the results of numerous gene mutations, including activation of oncogenes and inactivation of tumor suppressor genes (11,12). At present, the majority of studies have suggested that activation of oncogenes serves an important role in tumor occurrence and development (13,14). During the occurrence and development of tumors, tumor necrosis factor receptor-associated factor 6 (TRAF6) functions as a cancer gene (15,16). TRAF6 belongs to the Traf family; TRAF is a cytoplasmic adapter protein, which comprises a family of seven members (TRAF 1-7). These members serve important roles in various signaling pathways, including the tumor necrosis factor receptor superfamily and interleukin-1 receptor superfamily, which are involved in regulating cell survival and cell death (17-19). TRAF6 is closely associated with the maturation and differentiation of osteoclasts in vitro (20). Recent studies have reported that TRAF6 serves an important role in the development, invasion and metastasis of tumors by activating nuclear factor (NF)-κB (21,22). However, studies regarding the expression of TRAF6 in osteosarcoma and its biological role are rare.

Previous studies have revealed that TRAF6 is highly expressed in lung cancer, glioma and esophageal cancer, and it is associated with tumor invasion and metastasis (15,23-25). In addition, it has been suggested that TRAF6 may promote tumor angiogenesis (26). Our previous study indicated that TRAF6 mRNA and protein was highly expressed in osteosarcoma tissues (27). This finding was consistent with the expression pattern of TRAF6 in other tumors. Numerous studies have been conducted in the field of osteosarcoma; however, studies regarding the mechanism underlying the effects of TRAF6 on the pathogenesis of osteosarcoma are rare, and why TRAF6 expression is upregulated in osteosarcoma remains unclear. Therefore, research regarding the regulation of TRAF6 expression may have important theoretical significance and practical value.

In recent years, a novel method of gene expression regulation, namely microRNA (miRNA/miR) regulation, has been discovered (28,29). The present study aimed to determine whether the high expression of TRAF6 in osteosarcoma cells was due to miRNA regulation. Therefore, databases, whether the high expression of TRAF6 in osteosarcoma remains unclear. Therefore, research regarding the regulation of TRAF6 using an overexpression vector.

Materials and methods

Specimens. A total of 16 fresh osteosarcoma specimens and normal bone tissues were collected from patients with osteosarcoma (n=16; 8 male and 7 female; 11 younger than 40 years old and 5 older than 40 years old) by surgical excision; specimens were immediately stored in liquid nitrogen. None of the patients had a history of chemotherapy, radiotherapy or other treatments, and did not have other inflammatory diseases. The present study was approved by the Ethics Committee of Yancheng City No. 1 People's Hospital (Yancheng, China; approval no. 2015YCYY-0001). The patients provided written informed consent prior to sample collection.

Main reagents. The miR-124 reverse transcription (RT) primer (5'-GAT ACT CAT AAG GCA CGC GG-3' and 5' -GTG CAG GGT CCG AGGT-3'), miR-124 mimic and non-specific control (mimic control) were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). The TaqMan miRNA isolation kit, TaqMan miRNA assay and TaqMan Universal polymerase chain reaction (PCR) master mix were purchased from Applied Biosystems; Thermo Fisher Scientific, Inc. (Waltham, MA, USA).

Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM), Eagle's Minimum Essential medium (EMEM), L-glutamine and HEPES were purchased from Gibco; Thermo Fisher Scientific, Inc., and Lipofectamine 2000 was purchased from Invitrogen; Thermo Fisher Scientific, Inc. Nunc™ cell culture plates and culture dishes were obtained from Thermo Fisher Scientific, Inc., and the Transwell invasion chamber was purchased from Corning Incorporated (Corning, NY, USA).

MTT and radioimmuno precipitation assay (RIPA) lysis buffer were purchased from Beyotime Institute of Biotechnology (Shanghai, China). Trypsin, PBS and Hoescht 33342 were purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). Matrigel was purchased from BD Biosciences (Franklin Lakes, NJ, USA). Annexin V and propidium iodide (PI) were purchased from Roche Diagnostics (Indianapolis, IN, USA). Rabbit anti-human TRAF6 polyclonal antibody and mouse anti-human β-actin monoclonal antibody were purchased from Abcam (Cambridge, MA, USA). Horse radish peroxidase (HRP)-conjugated affinity-purified goat anti-mouse and goat anti-rabbit immunoglobulin (Ig)G secondary antibodies were purchased from Sigma-Aldrich; Merck KgaA. A protein extraction and quantification kit (BCA kit) was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA, USA).

The carrier pcdNA3.1, pGEM-T and pGL3-Basic vectors, competent cells (DH5α) and TRIzol® total RNA extraction kit were purchased from Invitrogen; Thermo Fisher Scientific, Inc. BamHI and Xhol restriction enzymes, and DNA Marker were purchased from Takara Bio, Inc. (Oslo, Japan). T4 DNA ligase was purchased from Promega Corporation (Madison, WI, USA). Taq DNA polymerase and prestrained protein marker were purchased from Fermentas; Thermo Fisher Scientific, Inc. Transcriptor First Strand cDNA synthesis kit was purchased from Qiagen GmbH (Hilden, Germany).
Cell treatment. MG-63 cells were purchased from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China), and were cultured in EMEM (2 mM L-glutamine, 1.0 mM sodium pyruvate, 0.1 mM non-essential amino-acid) containing 10% FBS. 293 cells were purchased from American Type Culture Collection (Manassas, VA, USA), and were cultured in DMEM containing 10% FBS.

Construction of recombinant TRAF6 expression plasmids. According to the human TRAF6 mRNA sequence in GenBank (GI: 1732425; https://www.ncbi.nlm.nih.gov/genbank/) and enzyme cleavage site analysis, a pair of primers was designed using Primer Premier 5 software (Premier Biosoft International, Palo Alto, CA, USA) in the two flanks of the open reading frame of TRAF6. The primer sequences were as follows: Upstream primer P1, 5'-CGGGATCCATGAGTCTGCTAAACTGTGA-3', which contained the BamHI enzyme cleavage site; and downstream primer P2, 5'-CCCTCGAGTACCCCTGATCAGTACTTC-3', which contained the XhoI enzyme cleavage site (the underlined sections of the primer sequences indicate the restriction endonuclease site). The primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China).

Culture MG-63 cells were uniformly inoculated into 6-well culture plates at 3x10^5/ml; the volume of each well was 1 ml. Subsequently, the cells were transfected with the luciferase plasmids containing TRAF6 3'-UTR (wild-type) or mutated TRAF6 3'-UTR (mutant), alongside the miR-124 mimic or mimic control. In addition, a normal control group was generated. A total of 48 h post-transfection, cells were collected and detected using a luciferase kit; a microplate reader was used for numerical readings at a wavelength of 560 nm.

Western blot analysis. Proteins were extracted from MG-63 cells using RIPA lysis buffer post-transfection with a miR-124 mimic or mimic control for 48 h. The concentration in the supernatant was then measured using the bicinchoninic acid method. Proteins (50 µg) were separated by 5-15% SDS-PAGE and were transferred onto a polyvinylidene fluoride membrane via Wet Transfer (Bio-Rad Laboratories, Inc.).

MTT assay. After MG-63 cells were transfected with a miR-124 mimic or mimic control for 48 h, they were incubated with 100 µl MTT (0.5 mg/ml) solution/well at 37°C for 4 h. Subsequently, 100 µl 20% SDS (auxiliary solvent, 50% dimethylformamide) was added to each well for 24 h at 37°C. A microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) was used to detect the optical density values at 570 nm. In addition, the normal control group was analyzed. A total of 10 complex holes were
set up in each experimental group, and the experiment was repeated three times.

**Flow cytometric detection of cell cycle progression.** MG-63 cells were transfected with a miR-124 mimic or mimic control for 48 h. In addition, a normal control group (normal) was generated. Subsequently, the cells were washed 1-2 times with PBS and trypsin was used to digest cells, after which cells were washed further 1-2 times with PBS and the cells were collected by centrifugation. PI was added to the cells, which were incubated in the dark for 30 min at 4°C. Finally, cells were filtered and underwent flow cytometric analysis (BD Biosciences). CellQuest software (BD Biosciences) was used to count cells, and FACSuite software (BD Biosciences) was used to analyze the data.

**Flow cytometric analysis of apoptosis.** MG-63 cells were transfected with a miR-124 mimic or mimic control for 48 h. In addition, a normal control group (normal) was generated. Subsequently, the cells were washed 1-2 times with PBS, and were incubated with Annexin V-fluorescein isothiocyanate and PI in the dark for 15 min at room temperature. Finally cells were filtered and underwent flow cytometric analysis (BD Biosciences) for the detection of apoptotic cells. CellQuest software (BD Biosciences) was used to count cells, and Mac quit software was used to analyze the data.

**Transwell invasion chamber assay.** Transfection of MG-63 cells with a miR-124 mimic and mimic control was conducted using Lipofectamine® 2000 according to the manufacturer's protocol. In addition, a normal control group (normal) was generated. MG-63 cells were transfected with the specified mimics for 24 h; after transfection, the cells were seeded in a Transwell invasion chamber and incubated for another 24 h, and after cultivation under normal conditions for 24 h, the cells were washed 1-2 times with PBS, and the cells were stained with Hoechst 33342. Eight visual fields were observed at random, and the number of cells that passed through the Transwell polycarbonate membrane was counted under a microscope (Leica DM IL; Leica, Wetzlar, Germany). Cells that passed through the Transwell polycarbonate membrane were considered invasive cells. The Transwell chamber wells were coated in Matrigel.

**Further validation of the role of TRAF6 in cell biology via miR-124 regulation.** In order to confirm that TRAF6 serves a role in cell biology via miR-124 regulation, a TRAF6 recombinant expression vector, pcDNA3.1-TRAF6, was constructed. The cells were divided into the following five groups: Normal control group (normal), empty vector control group (pcDNA3.1), pcDNA3.1-TRAF6 transfection group and miR-124 mimic + pcDNA3.1-TRAF6 transfection group. The miR-124 mimic and pcDNA3.1-TRAF6 were simultaneously transfected into MG-63 cells using Lipofectamine® 2000. For MTT assay, cultured MG-63 cells were uniformly inoculated into 96-well culture plates at 3x10⁵/ml; the volume of each well was 0.1 ml. A total of 300 ng pcDNA3.1-TRAF6 and 50 nM mimic were then diluted into 25 µl medium without serum. And 1 µl Lipofectamine® 2000 was diluted into 25 µl OptiMEM Medium and incubate for 5 min at room temperature. The DNA- mimic-Lipofectamine® 2000 complexes (50 µl) were directly added to each well of the plates containing cells and were then mixed gently. To further validate the role of TRAF6 in cell biology via miR-124 regulation, MTT, flow cytometry and Transwell analytical methods were used.

**Statistical analysis.** The data are presented as mean ± SD. The experiments were repeated 3 times. Statistical processing of experimental data was conducted using SPSS 17.0 statistical analysis software (SPSS, Inc., Chicago, IL, USA), and it was used to compare the differences between two groups. One-way analysis of variance was used to analyze the data and Tukey's post hoc test was used to analyze the differences between more than two groups. Student's t-test was used to analyze the differences between two groups. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Identification of TRAF6 as a target gene of miR-124.** In order to verify that the predicted miR-124 binding site was located in the TRAF6 3'-UTR, luciferase plasmids containing TRAF6
3′-UTR (wild-type) and mutated TRAF6 3′-UTR (mutant) were constructed, and were transfected into 293 cells alongside a miR-124 mimic or mimic control. The results demonstrated that compared with the control mimic group, luciferase activity was significantly decreased in the miR-124 mimic and TRAF6 3′-UTR (wild-type) group (P<0.01; Fig. 1A). These results indicated that miR-124 may directly act on the predicted target site of TRAF6 3′-UTR.

Western blot analysis was used to detect TRAF6 expression and the effects of miR-124 on its regulation. The results indicated that the protein expression levels of TRAF6 were significantly reduced in the miR-124 mimic group compared with in the normal and mimic control groups (P<0.01; Fig. 1B). These results suggested that overexpression of miR-124 inhibited the protein expression levels of TRAF6 protein.

miR-124 expression in human osteosarcoma tissues and cell lines. The results of RT-qPCR analysis demonstrated that the expression levels of miR-124 were significantly reduced in osteosarcoma tissues and MG-63 cells compared with in normal bone tissue (P<0.01; Fig. 2). These results suggested that miR-124 expression may be decreased in human osteosarcoma tissues and cell lines.

Effects of miR-124 on cell viability, as detected by MTT assay. Transfection of MG-63 cells with a miR-124 mimic induced miR-124 overexpression. The results of RT-qPCR analysis demonstrated that in the miR-124 mimic group, the expression levels of miR-124 were significantly increased compared with in the normal and mimic control groups (P<0.01; Fig. 3).

The results of the MTT analysis demonstrated that following transfection with a miR-124 mimic for 48 h, cell viability was significantly reduced compared with in the normal and mimic control groups (P<0.01; Fig. 4). These results indicated that miR-124 overexpression may reduce the viability of MG-63 cells.

Effects of miR-124 on cell cycle progression and apoptosis, as detected by flow cytometry. After MG-63 cells were transfected with a miR-124 mimic and mimic control for 48 h, flow cytometry was used to detect the proportion of cells in each phase of the cell cycle. The results indicated that in the miR-124 mimic group, the proportion of S phase cells and G2/M phase cells was significantly reduced compared with in the normal and mimic control groups (P<0.05), whereas the proportion of G0/G1 phase cells was significantly increased compared with in the normal and mimic control groups (P<0.05; Fig. 5A). These results indicated that miR-124 overexpression may inhibit cell cycle progression.

Flow cytometry was also used to determine the effects of miR-124 on cell apoptosis. The results demonstrated that in the miR-124 mimic group, the proportion of apoptotic cells was significantly higher compared with in the normal and mimic control groups (P<0.01; Fig. 5B). These results suggested that miR-124 overexpression may promote cell apoptosis.

Effects of miR-124 on cell invasion, as detected by Transwell invasion assay. After MG-63 cells were transfected with a miR-124 mimic and mimic control for 48 h, the number of cells that passed through the polycarbonate membrane of a Transwell invasion chamber was determined. Hoechst 33342 staining demonstrated that in the miR-124 mimic group, the number of cells that passed through the Transwell membrane was significantly decreased (P<0.01). In addition, the migration of MG-63 cells was inhibited post-transfection with a miR-124 mimic (Fig. 5C).

Validation of the role of miR-124 in cell biology via TRAF6 regulation. Our preliminary study confirmed that TRAF6...
MENG et al: EFFECTS OF TRAF6 ON OSTEOSARCOMA ARE REGULATED BY miR-124

served a role as a proto-oncogene in osteosarcoma (27). In addition, the results of the present study indicated that miR-124 may be considered a tumor suppressor gene in osteosarcoma, and TRAF6 was confirmed as a target gene regulated by miR-124. Therefore, the present study aimed to further validate the role of miR-124 in cell biology via TRAF6 regulation. Therefore, a recombinant expression plasmid of TRAF6 was constructed, after which MG-63 cells were cotransfected with a miR-124 mimic and the pcDNA3.1-TRAF6 recombinant expression vector using Lipofectamine® 2000. Subsequently, the cells were evaluated using MTT, flow cytometry and Transwell analytical methods (Fig. 6).

Firstly, western blot analysis was used to detect the protein expression levels of TRAF6 in each group. The results revealed that transfection of MG-63 cells with pcDNA3.1-TRAF6 significantly promoted TRAF6 expression (P<0.01). However, in the miR-124 mimic + pcDNA3.1-TRAF6 transfection group, TRAF6 expression was significantly reduced compared with in the pcDNA3.1-TRAF6 transfection group (P<0.01), and was slightly higher than that in the normal and pcDNA3.1 groups (P>0.05; Fig. 6A).

Cell viability was increased in the pcDNA3.1-TRAF6 transfection group, and the proportion of cells in the S + G2/M phase was increased. Furthermore, the number of cells that passed through the polycarbonate membrane was significantly higher compared with in the other groups (P<0.01). These results suggested that TRAF6 may be considered a proto-oncogene in osteosarcoma. Cell viability in the miR-124 mimic + pcDNA3.1-TRAF6 transfection group was decreased, and the numbers of cells in S + G2/M phase and that passed through the polycarbonate membrane were significantly reduced compared with in the pcDNA3.1-TRAF6 transfection group (P<0.01). Viability, cell cycle progression and invasion was slightly higher in the miR-124 mimic + pcDNA3.1-TRAF6 transfection group than in the normal and pcDNA3.1 groups (P>0.05; Fig. 6B, C and E). Furthermore, apoptosis was analyzed by flow cytometry, and the results revealed that in the miR-124 mimic + pcDNA3.1-TRAF6 transfection group, the number of apoptotic cells was significantly higher than in the normal and pcDNA3.1 groups (P>0.05; Fig. 6D). These results indicated that miR-124 overexpression could inhibit TRAF6-induced cell cycle progression of osteosarcoma cells and initiate apoptosis.
Discussion

Osteosarcoma often occurs in children and adolescents, and is one of the most common forms of primary malignant bone tumor (32,33). Osteosarcoma is associated with a high degree of malignancy and early blood metastasis; in addition, the incidence of pulmonary metastasis is high, disease development is rapid and it is associated with high levels of mortality (34,35). Increased information regarding the molecular mechanism underlying the occurrence and metastasis of osteosarcoma is required to serve a guiding role in gene-targeted therapy (36,37).

During tumor occurrence and development, TRAF6 has a functional role as a cancer gene (15,16). The TRAF6 protein is composed of four domains; a coiled-coil structural domain (also known as TRAF-N structural domain) and a conservative TRAF-C structural domain are contained in its C-terminal, which can interact with upstream receptors or other signaling proteins through self-association, thus resulting in exertion of its biological function (38,39). The N-terminal of the TRAF6 protein contains a RING finger structural domain (E3 ubiquitin ligase) and multiple zinc finger domains (bound with specific DNA sequences); these structures have important roles in the activation of downstream signals (40). In recent years, studies have revealed that TRAF6 has an important role in the development, invasion and metastasis of tumors by activating NF-κB (41,42). Our preliminary results indicated that TRAF6 expression is increased in osteosarcoma tissues; therefore it may be considered a proto-oncogene. These findings were validated in the present study. The present study aimed to explore the possible mechanism underlying the regulation of TRAF6 in osteosarcoma.

miRNAs are a class of evolutionarily conserved, non-protein coding RNAs (43-45), which are widely expressed in numerous organisms. Through the transcriptional regulation of target genes, miRNAs are involved in the regulation of several types of tumorigenesis and metastasis (46,47). In the present study, the miRNA that may regulate TRAF6 expression was analyzed using a series of online software, thus resulting in the identification of miR-124. Existing research indicated that through the downregulation of Rho-associated protein kinase 1, miR-124 may inhibit the proliferation and migration of colon cancer cells (48). In astrocytoma, miR-124 has been reported to regulate cell proliferation, apoptosis and migration via proto-oncogene serine/threonine-protein kinase Pim-1 (49). In the present study, the results of a luciferase reporter gene system demonstrated that in the miR-124 mimic group, luciferase activity was significantly decreased, and western blotting revealed that the overexpression of miR-124 inhibited the expression of TRAF6. These findings verified TRAF6 as a target gene regulated by miR-124.

In the present study, RT-qPCR was used to detect the expression levels of miR-124 in osteosarcoma tissues; the results revealed that miR-124 expression was downregulated in osteosarcoma tissues and cells. Subsequently, miR-124 was overexpressed in MG-63 cells via transfection with a miR-124 mimic. The biological effects of miR-124 overexpression were then examined using MTT, flow cytometry and Transwell invasion assay analytical methods. The results demonstrated that miR-124 overexpression decreased cell viability, inhibited cell cycle progression and invasion, and promoted apoptosis.
Therefore, it may be hypothesized that miR-124 participates in the occurrence and metastasis of the osteosarcoma malignant phenotype by regulating TRAF6 and associated downstream signaling pathways. In the present study, miR-124 overexpression in osteosarcoma cells reduced TRAF6 expression, thus inhibiting cell cycle progression and invasion of osteosarcoma cells, and promoting osteosarcoma cell apoptosis. In order to further verify the role of TRAF6 in cell biology via miR-124 regulation, the present study constructed a TRAF6 recombinant expression vector, pcDNA3.1-TRAF6. Subsequently, MG-63 cells were cotransfected with pcDNA3.1-TRAF6 and a miR-124 mimic, and MTT, flow cytometry and Transwell invasion assay analytical methods were used to analyze the effects. The results suggested that miR-124 overexpression could reverse the effects of TRAF6 overexpression on osteosarcoma cells, and promote apoptosis.

In conclusion, downregulation of miR-124 in human osteosarcoma tissues and cell lines may increase the expression of TRAF6 protein. miR-124 may inhibit cell cycle progression and invasion of osteosarcoma cells, and promote apoptosis by regulating TRAF6. Therefore, therapeutic strategies that enhance the expression of miR-124 or inhibit the expression of TRAF6 may benefit patients with osteosarcoma.

Acknowledgements
Not applicable.

Funding
The present study was supported by the National Natural Science Foundation of China (grant no. 81402226).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
QM and WZ designed the research and wrote the manuscript. XX, JL, HM, XL, LQ, XZ and MZ collected the data, analyzed and interpreted the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by the Ethics Committee of Yancheng City No. 1 People's Hospital (Yancheng, China; approval no. 2015CYY-0001). The patients provided written informed consent prior to sample collection.

Consent for publication
The patients provided written informed consent for the use of data in this study.

Competing interests
The authors declare that they have no competing interests.

References


